Stay updated on Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial
Sign up to get notified when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.

Latest updates to the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page
- CheckyesterdayChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe Publications section was updated to include the 2024 Blood article by Friedberg et al. on frontline brentuximab vedotin therapy for older HL patients ineligible for chemotherapy, and the Erratum for that Blood article was removed.SummaryDifference0.0%

- Check30 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 from the page; this appears to be a maintenance/versioning update with no changes to study content.SummaryDifference0.0%

- Check37 days agoChange DetectedFooter now displays Revision: v3.4.3 instead of Revision: v3.4.2.SummaryDifference0.0%

- Check44 days agoChange DetectedThe Blood 2024 publication citation Friedberg et al. was added and subsequently removed from the Publications section.SummaryDifference0.0%

- Check65 days agoChange DetectedFooter now shows Revision: v3.4.2, replacing the previous Revision: v3.4.1. The notice about lapse in government funding was removed.SummaryDifference0.3%

Stay in the know with updates to Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.